Liver Cancer Podcast

by International Liver Cancer Association (ILCA)

In this podcast, the ILCA Communications Committee will cover the most recent papers in liver cancer research and some of the key sessions from industry events. Join in for an interactive summary of the latest in liver cancer and hear from our ILCA experts as well as some special guests!

Podcast episodes

  • Season 3

  • ILCA Advocacy: Improving Tumour Board

    ILCA Advocacy: Improving Tumour Board

    In this episode, Lorenza Rimassa, Andrew Moon, and Jakob Kather discuss ways to enhance tumor board effectiveness. Lorenza emphasizes the importance of multidisciplinary collaboration, Andrew highlights patient representation, and Jakob explores the integration of AI. Listen to them as they engage in insightful exchanges, addressing questions and offering innovative solutions. This episode is sponsored by Roche, a global pioneer in pharmaceuticals and diagnostics. Roche's goal is to partner with the HCC community to provide optimal care and treatment to patients with HCC by supporting the implementation of an MDT approach.

  • Best oral presentations from ILCA23

    Best oral presentations from ILCA23

    Meet Antonio D'Alessio and Claudia Campani, two of the best oral presenters from the ILCA 2023 Annual Conference. Antonio will present and discuss his work "Predictors of response to neoadjuvant immunotherapy in resectable hepatocellular carcinoma: preliminary clinical and translational analyses from the PRIME-HCC study". Claudia will present her work "Dynamic evolution of circulating tumor DNA in patients with hepatocellular carcinoma across tumor stages and treatments". Incyte has co-funded this podcast and all content has been developed independently by ILCA.

  • Liver Transplantation for perihiliar cholangiocarcinoma: do we need to move forward?

    Liver Transplantation for perihiliar cholangiocarcinoma: do we need to move forward?

    In this episode, Dr Taizo Hibi and Dr Cristina Dopazo discuss a recent review article in Hepatoma Research titled: “Liver Transplantation for perihiliar cholangiocarcinoma: Do we need to move forward?". They discuss the outstanding results of the Mayo Clinic protocol based on liver transplantation after neoadjuvant chemoradiation in very selected patients with unresectable de novo pCCA or resectable pCCA arising under primary sclerosing cholangitis. However, its application is diverse worldwide. They also discuss the recommended tools for diagnostic work-up, the need for updating the systemic therapy following the results of the latest clinical trials, the role of cfDNA, and the importance of multicenter collaborations. This episode is sponsored by Hepatoma Research.

  • Challenges and barriers in HCC surveillance for patients with non-alcoholic fatty liver disease

    Challenges and barriers in HCC surveillance for patients with non-alcoholic fatty liver disease

    This episode discusses a recent review article in Hepatoma Research titled: "Challenges and Barriers in Hepatocellular Carcinoma Surveillance for Patients with non-alcoholic Fatty Liver Disease" (now called metabolic associated steatotic liver disease or MASLD). We discuss several important challenges and barriers that currently exist in caring for patients with MASLD cirrhosis, including the scale of the MASLD – hepatocellular carcinoma problem, the current lack and limitations of accurate risk stratification tools in order to improve detection and prevention of HCC in patients with MASLD cirrhosis, potential solutions to address these limitations, and ends with a discussion of current disparities that exist in HCC surveillance. This episode is sponsored by Hepatoma Research.

  • ASCO GI 2023 Highlights: Updates on HCC & CCA

    ASCO GI 2023 Highlights: Updates on HCC & CCA

    In this episode, Drs. Maria Reig and Richard Finn will dive deep into the updates and groundbreaking research presented at the ASCO GI Meeting in January 2023. They will explore the latest advancements in the field of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Here is what you can expect from this podcast: • Updates on the efficacy and safety of new drugs in HCC • The evolving landscape of systemic therapy for cholangiocarcinoma • Evolving questions in sequencing systemic therapy in HCC • The role of systemic therapy in the early stages of HCC Incyte has co-funded this podcast and all content has been developed independently by ILCA.